首页> 外国专利> Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV

Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV

机译:用于抑制磷酸二酯酶IV的基于苯酚或苄基取代的咯利普兰的化合物及其方法

摘要

Rolipram-based PDE IV inhibitors containing phenyl- or benzyl- substituted moieties of the formula: ##STR1## wherein X.sub.1 and X.sub.2 may be the same or different and each is O or S;PPR.sub.1 is selected from the group consisting of hydrogen, saturated or unsaturated straight-chain or branched C.sub.2-12 alkyl groups, cycloalkyl and cycloalkyl-alkyl groups containing from 3 to 10 carbon atoms in the cycloalkyl moiety;PPR.sub.2 =R.sub.1 or --CH. sub.3 ;PPR.sub.3 is hydrogen, halogen, or a saturated or unsaturated straight-chain or branched C.sub.1-12 alkyl group, a cycloalkyl or cycloalkyl-alkyl groups containing from 3 to 7 carbon atoms in the cycloalkyl moiety;PPZ is a linkage selected from -- CH.sub.2 CONH-- or --CH.sub.2 NHCO--, andPPR.sub.4 is a phenyl or benzyl which may be unsubstituted or substituted with one or more halogen atoms, alkyl groups, hydroxyl groups, cyano groups, carboxyl groups, alkoxy groups, alkoxycarbonyl, amido, carboxamido, substituted or unsubstituted amino groups, cycloalkyl and cycloalkyl-alkyl groups containing from 3 to 10 carbon atoms in the cycloalkyl moiety, aryl or aralkyl groups preferably containing from about 6 to about 10 carbon atoms, or heterocyclic groups containing nitrogen, oxygen or sulfur in the ring; the alkyl, alkoxy, cycloalkyl, cycloalkylalkyl, aryl, and aryl- alkyl groups being saturated or unsaturated, unsubstituted or substituted by halogen atoms, hydroxyl groups, cyano groups, carboxyl groups, alkoxy groups, alkoxycarbonyl, carboxamido or substituted or unsubstituted amino groups, or one or more lower alkyl groups having from 1 to 3 carbon atoms; PPprovided that R.sub.4 cannot be substituted with more than one methoxy group. compared to theophylline or rolipram as well as with improved selectivity with regard to PDE III inhibition. Pharmaceutical compositions containing the same and methods of treatment are also disclosed.
机译:含有下式的苯基或苄基取代基团的基于咯利普兰的PDE IV抑制剂:其中X.sub.1和X.sub.2可以相同或不同,并且各自为O或S;

P> R.sub.3是氢,卤素或饱和或不饱和的直链或支链C1-12烷基,环烷基或环烷基-烷基,含3环烷基部分中的碳原子数为7个; P 是选自-CH 2 CONH--或--CH 2 NHCO--和

R 4是可以未被取代或被一个或多个卤素原子,烷基,羟基,氰基,羧基,烷氧基,烷氧羰基,酰胺基,羧酰胺基,取代或未取代的氨基取代的苯基或苄基,在环烷基部分中含有3至10个碳原子的环烷基和环烷基-烷基,优选地含有约6至约10个碳原子的芳基或芳烷基,或在环中含有氮,氧或硫的杂环基;烷基,烷氧基,环烷基,环烷基烷基,芳基和芳基-烷基是饱和或不饱和的,未被取代或未被卤素原子,羟基,氰基,羧基,烷氧基,烷氧基羰基,羧酰胺基或取代或未取代的氨基取代,一个或多个具有1至3个碳原子的低级烷基;或

提供了R.sub.4不能被一个以上的甲氧基取代的情况。与茶碱或咯利普兰相比,对PDE III的抑制作用具有更高的选择性。还公开了包含其的药物组合物和治疗方法。

著录项

  • 公开/公告号US5591776A

    专利类型

  • 公开/公告日1997-01-07

    原文格式PDF

  • 申请/专利权人 EURO-CELTIQUE S.A.;

    申请/专利号US19950370952

  • 申请日1995-01-10

  • 分类号A61K31/165;C07C233/08;

  • 国家 US

  • 入库时间 2022-08-22 03:10:49

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号